News

Building a Biomedical Information Commons: Ethical and Policy Issues

Explore the pros and cons of managing genetic information via public and proprietary companies.

Cross-Cultural Perspectives on Brain Death

Even in the US, some controversy persists over the conceptual defensibility of brain death. Around the world, the philosophical defensibility of brain death is even more debatable.

Of medicine and ethics

Harvard Gazette
By John Laidler, Harvard Correspondent
Shifts in the field can allow providers both to prosper and serve patients better, speaker James Corbett says.

2016 Annual Bioethics Conference -- Social Justice and Ethics Committees in Health Care: Core to our Mission or None of our Business?

This multidisciplinary program was co-sponsored by the Center for Bioethics at Harvard Medical School and

Ethical Imperative and Moral Challenges of Engaging Patients and the Public with Health Care Evidence

A national conversation about the evidence behind health care and health policy options is an “ethical imperative,” but values conflicts are likely to arise. Dr. Mille Solomon and scholars from the Hastings Center propose a way forward in an article in Health Affairs.

Thos Cochrane: Connecting Morality and the Mind

How one faculty member defines the world of neuroethics

An Uninformative Truth: The Logic of Amarin's Off-Label Promotion

Center faculty members Dr. Spencer Hey and Dr. Aaron Kesselheim examined a lawsuit filed by Amarin Pharmaceutical in May 2015 that sought permission to distribute "truthful and non-misleading" statements relating to an off-label use of its product Vascepa, a pill derived from fish oil. The authors conclude that "informativeness," understood as asserting scientific facts--beyond mere logical truth--"ought to be the standard for regulating commercial speech about pharmaceuticals".